FEMY Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.74
- P/S (TTM)
- 5.40
- EV/EBITDA
- 0.24
Profitability & growth
- ROE (TTM)
- -256.0%
- Operating margin
- -994.0%
- Revenue growth YoY
- 24.5%
- Dividend yield
- —
- Beta
- -2.22
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Femasys Inc
Company profileFemasys Inc. is a pioneering medical technology company focused on revolutionizing women's healthcare with its proprietary, non-surgical solutions for diagnosing and treating gynecological conditions, including uterine fibroids and contraception. By addressing significant unmet needs in women's health, Femasys is positioned to benefit from the growing demand for minimally invasive treatments, which enhance patient outcomes and improve healthcare efficiency. The company's innovative approach aims to set new standards of care, reinforcing its commitment to transforming the landscape of women's…
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3950 JOHNS CREEK COURT, SUWANEE, GA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer